We are committed to finding a cure for WM.
Article: Ibrutinib Monotherapy in Symptomatic, Treatment-Naive Patients with Waldenstrom Macroglobulinemia
Abstract:
Purpose
Ibrutinib is active in previously treated Waldenstro¨m macroglobulinemia (WM). MYD88 mutations
(MYD88MUT) and CXCR4 mutations (CXCR4MUT) affect ibrutinib response. We report on a prospective
study of ibrutinib monotherapy in symptomatic, untreated patients with WM, and the effect
of… Continue reading
Event: 5th International Patient and Physicians Summit
5th International Patient and Physician Summit on Waldenstrom’s Macroglobulinemia (WM).
The Summit will take place on October 13-14, 2018, at the New York Marriott Downtown Hotel and Conference Center, situated in Lower Manhattan next to the Freedom Tower. The… Continue reading
